Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retinoblastoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Retinoblastoma. Displaying page 1 of 1.
    EudraCT Number: 2019-000742-35 Sponsor Protocol Number: RTBAIEOP018 Start Date*: 2021-05-05
    Sponsor Name:ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: PROTOCOL FOR THE DIAGNOSIS AND THERAPY OF INTRAOCULAR RETINOBLASTOMA
    Medical condition: Intraocular retinoblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038916 Retinoblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038916 Retinoblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038916 Retinoblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038916 Retinoblastoma PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005673-21 Sponsor Protocol Number: AIEOP RB 05 Start Date*: 2006-01-01
    Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: PROTOCOL OF DIAGNOSIS AND THERAPY FOR RETINOBLASTOMA - AIEOP RB 05
    Medical condition: retinoblastoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038916 PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-006109-85 Sponsor Protocol Number: RTBAIEOP012 Start Date*: 2012-02-14
    Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: DIAGNOSTIC AND THERAPEUTIC STUDY FOR NEWLY DIAGNOSED RETINOBLASTOMA PATIENTS RTB AIEOP 012
    Medical condition: Newly diagnosed retinoblastoma patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10038916 Retinoblastoma PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001060-11 Sponsor Protocol Number: FSJD-RTB-2015 Start Date*: 2017-08-03
    Sponsor Name:Fundació Sant Joan de Déu
    Full Title: A Phase I, unicentric, open and dose escalation clinical trial to evaluate the safety and the activity of the oncolytic adenovirus VCN-01 in patients with refractory retinoblastoma
    Medical condition: Refractory Retinoblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038916 Retinoblastoma PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003621-10 Sponsor Protocol Number: IC2011.05 Start Date*: Information not available in EudraCT
    Sponsor Name:INSTITUT CURIE
    Full Title: CONSERVATIVE TREATMENT OF PATIENTS WITH RETINOBLASTOMA
    Medical condition: RETINOBLASTOMA
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10038918 Retinoblastoma NOS LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016448-38 Sponsor Protocol Number: IC 2009-04 Start Date*: 2009-12-15
    Sponsor Name:Institut Curie
    Full Title: Traitement adjuvant dans les rétinoblastomes unilatéraux étendus énucléés d’emblée.
    Medical condition: Rétinoblastomes unilatéraux étendus énucléés d’emblée.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10038916 Retinoblastoma LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010737-47 Sponsor Protocol Number: HSJD-RTB-QTIA Start Date*: 2009-06-12
    Sponsor Name:HOSPITAL SANT JOAN DE DÉU
    Full Title: Ensayo de fase II, no randomizado, abierto, unicéntrico, de quimioterapia intraarterial con melfalán para el tratamiento del retinoblastoma (RTB) en fase intraocular avanzada. Phase II trial, no...
    Medical condition: RETINOBLASTOMA UNILATERAL AVANZADO ADVANCED INTRAOCULAR RETINOBLASTOMA
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005583-14 Sponsor Protocol Number: ART-OFT-RTB-SI-2008 Start Date*: 2008-09-15
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: NEW CONSERVATIVE THERAPIES IN RETINOBLASTOMA: DIRECT INTRAARTERIAL (OPHTALMIC ARTERY) CHEMOTHERAPY WITH MELPHALAN FOR INTRAOCULAR RETINOBLASTOMA
    Medical condition: patients with retinoblastoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015919 Eye disorders SOC
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-005039-94 Sponsor Protocol Number: IC2019-05 Start Date*: 2020-12-08
    Sponsor Name:Institut Curie
    Full Title: RETINO 2018 : Ocular conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome.
    Medical condition: Retinoblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001590-68 Sponsor Protocol Number: 03-133 Start Date*: 2020-11-26
    Sponsor Name:Y-mAbs Therapeutics Inc.
    Full Title: Phase I Study Of Intrathecal Radioimmunotherapy Using 131I-Omburtamab for Central Nervous System/Leptomeningeal Neoplasms
    Medical condition: Treatment of pediatric neuroblastoma patients with CNS relapse as evidenced by CNS/LM metastases
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073130 Central nervous system neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002825-31 Sponsor Protocol Number: INTV-STC-RT-SI-2012 Start Date*: 2012-07-01
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: NEW CONSERVATIVE THERAPIES IN RETINOBLASTOMA: INTRAVITREAL AND SUBCONJUNCITIVAL INJECTION OF CHEMOTHERAPY in the intraoculars RTBs
    Medical condition: patients with RTB
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10030054 Ocular neoplasms HLGT
    14.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003946-99 Sponsor Protocol Number: GETHI021 Start Date*: 2017-06-19
    Sponsor Name:Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI)
    Full Title: A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors presenting in adulthood
    Medical condition: Pediatric solid tumors presenting in adulthood
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022515-20 Sponsor Protocol Number: A5481004 Start Date*: 2011-02-22
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017, USA
    Full Title: PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF PD 0332991 IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA
    Medical condition: Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001848-20 Sponsor Protocol Number: ENGOT-EN3-NSGO/PALEO Start Date*: 2016-09-28
    Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU)
    Full Title: A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive...
    Medical condition: Histological confirmed endometrial cancer of endometrioid type. Mixed tumor histology is allowed if the non-endometrioid component is less than 5%. Tumour must be estrogen receptor positive.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014741 Endometrial cancer stage IV PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014735 Endometrial cancer NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014740 Endometrial cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) FI (Completed) DE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003892-31 Sponsor Protocol Number: MedOPP089 Start Date*: 2017-03-23
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: A multicenter, international, non-controlled, phase II trial to identify the molecular mechanisms of resistance and sensitivity to palbociclib re-challenge upon progression to a palbociclib combina...
    Medical condition: Patients with hormone receptor (HR)-positive/HER2-negative locally advanced or metastatic breast cancer (mBC). Second/third-line of endocrine treatment.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:20:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA